• Consensus Rating: Moderate Buy
  • Consensus Price Target: $266.00
  • Forecasted Upside: 4.79%
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$253.84
▲ +1.11 (0.44%)

This chart shows the closing price for DHR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Danaher Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DHR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DHR

Analyst Price Target is $266.00
▲ +4.79% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Danaher in the last 3 months. The average price target is $266.00, with a high forecast of $300.00 and a low forecast of $205.00. The average price target represents a 4.79% upside from the last price of $253.84.

This chart shows the closing price for DHR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 15 investment analysts is to moderate buy stock in Danaher. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/1/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
3/1/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/30/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
8/28/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/26/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/25/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2024KeyCorpBoost TargetOverweight ➝ Overweight$260.00 ➝ $290.00Low
1/31/2024CitigroupBoost TargetBuy ➝ Buy$255.00 ➝ $280.00Low
1/31/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$254.00 ➝ $282.00Low
1/31/2024Raymond JamesBoost TargetOutperform ➝ Outperform$240.00 ➝ $270.00Low
1/24/2024BarclaysDowngradeOverweight ➝ Equal Weight$240.00Low
12/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$250.00 ➝ $270.00Low
12/18/2023HSBCInitiated CoverageHoldLow
12/13/2023Wolfe ResearchInitiated CoveragePeer PerformLow
12/11/2023CitigroupBoost TargetBuy ➝ Buy$240.00 ➝ $255.00Low
12/7/2023The Goldman Sachs GroupDowngradeBuy ➝ Neutral$215.00 ➝ $205.00Low
10/26/2023BarclaysLower TargetOverweight ➝ Overweight$290.00 ➝ $215.00Low
10/26/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$250.00 ➝ $215.00Low
10/25/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$260.00 ➝ $250.00Low
10/25/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$246.00 ➝ $239.00Low
10/25/2023KeyCorpLower TargetOverweight ➝ Overweight$300.00 ➝ $260.00Low
10/25/2023CitigroupLower TargetBuy ➝ Buy$265.92 ➝ $240.00Low
10/25/2023Raymond JamesLower TargetOutperform ➝ Outperform$250.00 ➝ $240.00Low
10/18/2023Raymond JamesLower TargetOutperform ➝ Outperform$290.00 ➝ $250.00Low
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$300.00 ➝ $260.00Low
10/3/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$285.00 ➝ $247.00Low
9/27/2023KeyCorpLower TargetOverweight ➝ Overweight$325.00 ➝ $300.00Low
7/26/2023Royal Bank of CanadaBoost Target$260.00 ➝ $292.00Low
7/26/2023Stifel NicolausLower TargetHold$250.00 ➝ $240.00Low
7/26/2023Bank of AmericaBoost Target$250.00 ➝ $280.00Low
7/26/2023Raymond JamesBoost TargetOutperform$270.00 ➝ $290.00Low
7/25/2023BarclaysBoost TargetOverweight$260.00 ➝ $290.00Low
7/18/2023Raymond JamesInitiated CoverageOutperform$270.00Low
5/1/2023SVB LeerinkReiterated RatingOutperformLow
5/1/2023SVB SecuritiesInitiated CoverageOutperform$300.00Low
4/27/2023Deutsche Bank AktiengesellschaftLower Target$310.00 ➝ $275.00Low
4/26/2023William BlairReiterated RatingOutperformLow
4/26/2023Stifel NicolausLower Target$270.00 ➝ $250.00Low
4/26/2023Royal Bank of CanadaLower Target$289.00 ➝ $260.00Low
4/26/2023CitigroupLower Target$325.00 ➝ $300.00Low
4/26/2023Robert W. BairdLower Target$309.00 ➝ $275.00Low
4/26/2023Credit Suisse GroupLower Target$300.00 ➝ $270.00Low
4/26/2023BarclaysLower Target$270.00 ➝ $260.00Low
4/26/2023Bank of AmericaDowngradeBuy ➝ Neutral$310.00 ➝ $250.00Low
4/18/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$275.00 ➝ $285.00Low
4/4/2023BarclaysLower TargetOverweight$290.00 ➝ $270.00Low
1/25/2023CowenLower TargetOutperform$340.00 ➝ $320.00Low
1/25/2023Robert W. BairdLower Target$321.00 ➝ $309.00Low
1/24/2023Robert W. BairdBoost TargetOutperform$315.00 ➝ $321.00Low
1/24/2023BarclaysBoost TargetOverweight$277.00 ➝ $290.00Low
1/5/2023Credit Suisse GroupDowngradeOutperform ➝ Neutral$315.00 ➝ $300.00Low
12/13/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$310.00Low
11/29/2022BarclaysLower TargetOverweight$285.00 ➝ $277.00Low
10/27/2022Credit Suisse GroupLower Target$315.00Low
10/24/2022BenchmarkDowngradeBuy ➝ Hold$325.00Low
10/21/2022Robert W. BairdLower TargetOutperform$325.00 ➝ $315.00Low
10/21/2022JPMorgan Chase & Co.Lower TargetOverweight$350.00 ➝ $315.00Low
10/21/2022Royal Bank of CanadaLower TargetOutperform$318.00 ➝ $302.00Low
10/6/2022BarclaysLower TargetOverweight$310.00 ➝ $305.00Low
9/20/2022BenchmarkLower TargetBuy$345.00 ➝ $325.00Low
9/16/2022Royal Bank of CanadaBoost TargetOutperform$317.00 ➝ $318.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$340.00Low
8/16/2022Sanford C. BernsteinInitiated CoverageOutperform$330.00 ➝ $340.00Low
7/28/2022UBS GroupBoost TargetBuy$297.00 ➝ $323.00Low
7/22/2022CowenLower Target$340.00Low
7/22/2022KeyCorpLower TargetOverweight$345.00 ➝ $325.00Low
7/22/2022Robert W. BairdBoost Target$319.00 ➝ $325.00Low
7/22/2022BarclaysBoost Target$290.00 ➝ $310.00Low
7/20/2022UBS GroupInitiated CoverageBuy$297.00Low
7/13/2022BarclaysLower TargetOverweight$320.00 ➝ $290.00N/A
7/5/2022Evercore ISILower TargetOutperform ➝ Outperform$320.00 ➝ $280.00N/A
6/1/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$299.00 ➝ $310.00Medium
4/25/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$330.00 ➝ $265.00Low
4/24/2022UBS GroupLower Target$365.00 ➝ $340.00Medium
4/22/2022William BlairReiterated RatingOutperformHigh
4/22/2022Robert W. BairdLower TargetOutperform$334.00 ➝ $319.00High
4/22/2022Royal Bank of CanadaLower TargetSector Perform$311.00 ➝ $299.00High
1/28/2022Royal Bank of CanadaLower Target$344.00 ➝ $302.00High
1/28/2022Wells Fargo & CompanyLower TargetOverweight$350.00 ➝ $330.00High
1/28/2022Robert W. BairdLower Target$340.00 ➝ $334.00High
1/27/2022BarclaysLower TargetOverweight$355.00 ➝ $325.00Medium
1/10/2022Sanford C. BernsteinInitiated CoverageOutperform$365.00Low
12/14/2021Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$340.00 ➝ $350.00High
10/22/2021KeyCorpBoost TargetOverweight$315.00 ➝ $345.00Low
10/22/2021BarclaysBoost TargetOverweight$335.00 ➝ $355.00Low
10/22/2021Royal Bank of CanadaBoost TargetSector Perform$332.00 ➝ $334.00Low
10/22/2021Robert W. BairdBoost TargetOutperform$305.00 ➝ $340.00Low
10/22/2021CitigroupBoost TargetBuy$345.00 ➝ $370.00Low
9/10/2021Bank of AmericaBoost TargetBuy$340.00 ➝ $360.00Low
9/10/2021Credit Suisse GroupBoost TargetPositive ➝ Outperform$306.00 ➝ $370.00Low
9/8/2021Royal Bank of CanadaBoost TargetSector Perform$304.00 ➝ $332.00Low
7/23/2021The Goldman Sachs GroupBoost TargetBuy$280.00 ➝ $320.00Low
7/23/2021CowenBoost TargetPositive ➝ Outperform$275.00 ➝ $350.00Low
7/23/2021BarclaysBoost TargetOverweight$310.00 ➝ $335.00Low
7/23/2021Robert W. BairdBoost TargetOutperform$270.00 ➝ $305.00Low
7/23/2021Royal Bank of CanadaBoost TargetSector Perform$285.00 ➝ $304.00Low
7/16/2021BenchmarkInitiated CoverageBuy$330.00Medium
7/13/2021BarclaysBoost TargetOverweight$300.00 ➝ $310.00Low
6/18/2021Credit Suisse GroupBoost TargetOutperform$282.00 ➝ $288.00Low
4/26/2021William BlairReiterated RatingOutperformLow
4/26/2021BarclaysBoost TargetOverweight$265.00 ➝ $300.00Low
4/23/2021CitigroupBoost Target$275.00 ➝ $315.00Low
4/23/2021KeyCorpBoost TargetOverweight$280.00 ➝ $315.00High
4/23/2021Jefferies Financial GroupBoost TargetBuy$270.00 ➝ $290.00High
4/23/2021Robert W. BairdBoost TargetOutperform$249.00 ➝ $270.00High
4/23/2021Wells Fargo & CompanyBoost TargetOverweight$260.00 ➝ $280.00High
4/23/2021Royal Bank of CanadaBoost TargetSector Perform$253.00 ➝ $285.00High
3/8/2021BarclaysInitiated CoverageOverweight$260.00N/A
3/2/2021BarclaysInitiated CoverageOverweight$260.00Medium
1/14/2021Credit Suisse GroupBoost TargetOutperform$260.00 ➝ $264.00Low
12/2/2020The Goldman Sachs GroupInitiated CoverageBuy$250.00Low
11/25/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$273.00 ➝ $234.00Low
11/9/2020KeyCorpInitiated CoverageOverweight$280.00High
10/27/2020Needham & Company LLCBoost Target$209.00 ➝ $272.00Low
10/23/2020Royal Bank of CanadaBoost TargetOutperform$250.00 ➝ $273.00Medium
10/23/2020Robert W. BairdBoost TargetOutperform$205.00 ➝ $252.00Medium
9/29/2020Wells Fargo & CompanyReiterated RatingBuy$234.00Low
7/27/2020Needham & Company LLCBoost TargetBuy$183.00 ➝ $209.00Low
7/27/2020UBS GroupBoost TargetBuy$176.00 ➝ $233.00Low
7/24/2020Stifel NicolausBoost TargetHold$170.00 ➝ $210.00Low
7/24/2020Jefferies Financial GroupBoost TargetBuy$190.00 ➝ $230.00Low
7/24/2020Robert W. BairdBoost TargetOutperform$163.00 ➝ $205.00Medium
7/24/2020Royal Bank of CanadaBoost TargetOutperform$205.00 ➝ $218.00Medium
7/20/2020Bank of AmericaBoost TargetBuy$181.00 ➝ $215.00Low
7/20/2020Royal Bank of CanadaReiterated RatingBuy$205.00Low
6/16/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$195.00Low
5/21/2020Credit Suisse GroupBoost TargetOutperform$165.00 ➝ $169.00Low
5/15/2020Needham & Company LLCLower TargetBuy$187.00 ➝ $183.00High
5/11/2020Royal Bank of CanadaBoost TargetIn-Line ➝ Outperform$159.00 ➝ $173.00Low
5/8/2020Stifel NicolausBoost TargetHold$147.00 ➝ $170.00Low
5/8/2020CitigroupBoost TargetBuy$180.00 ➝ $190.00High
5/7/2020Bank of AmericaBoost TargetBuy$160.00 ➝ $181.00Medium
4/21/2020Wells Fargo & CompanyBoost TargetOverweight$155.00 ➝ $170.00Medium
4/20/2020CitigroupBoost TargetBuy$160.00 ➝ $180.00Low
4/2/2020Stifel NicolausLower TargetHold$162.00 ➝ $147.00Medium
4/2/2020Wolfe ResearchDowngradeOutperform ➝ Market Perform$154.00High
3/30/2020Wells Fargo & CompanyLower TargetOverweight$176.00 ➝ $155.00Medium
3/26/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformLow
3/25/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$151.00 ➝ $157.00High
3/23/2020Robert W. BairdReiterated RatingBuy$136.00High
3/20/2020CitigroupLower TargetBuy$195.00 ➝ $160.00Medium
2/3/2020CowenReiterated RatingBuy$170.00High
2/3/2020Needham & Company LLCBoost TargetBuy$167.00 ➝ $187.00Low
1/31/2020Bank of AmericaBoost TargetBuy$165.00 ➝ $188.00Low
1/31/2020Robert W. BairdBoost TargetOutperform$160.00 ➝ $175.00High
1/31/2020Stifel NicolausBoost TargetHold$150.00 ➝ $162.00High
1/31/2020CitigroupBoost TargetBuy$180.00 ➝ $195.00High
1/30/2020Piper SandlerBoost Target$142.00 ➝ $174.00High
1/10/2020UBS GroupBoost TargetNeutral$165.00 ➝ $176.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$170.00Low
1/6/2020CitigroupInitiated CoverageBuy$180.00Low
1/2/2020Needham & Company LLCBoost TargetBuy$152.00 ➝ $167.00Low
12/19/2019JPMorgan Chase & Co.Boost Target$155.00 ➝ $175.00Medium
12/19/2019Credit Suisse GroupBoost TargetOutperform$151.00 ➝ $160.00Low
12/18/2019Royal Bank of CanadaReiterated RatingHold$145.00Medium
12/2/2019UBS GroupBoost TargetBuy$158.00 ➝ $165.00Low
11/14/2019Stifel NicolausReiterated RatingHold$150.00High
10/28/2019Needham & Company LLCLower TargetBuy$155.00 ➝ $152.00Low
10/25/2019Wolfe ResearchSet TargetBuy$154.00N/A
10/14/2019Credit Suisse GroupReiterated RatingOutperform$151.00Low
9/26/2019Wolfe ResearchSet TargetBuy$157.00Medium
7/23/2019ArgusBoost TargetBuy$165.00Low
7/19/2019Royal Bank of CanadaSet TargetHold$134.00Low
7/19/2019Robert W. BairdBoost TargetOutperform$131.00 ➝ $148.00Low
7/19/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$142.00 ➝ $155.00Low
7/18/2019Piper Sandler CompaniesBoost TargetNeutral$148.00 ➝ $153.00Low
6/11/2019Piper Sandler CompaniesInitiated CoverageNeutral ➝ Neutral$148.00Low
5/30/2019Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
4/17/2019Janney Montgomery ScottBoost TargetBuy$136.00 ➝ $174.00Medium
4/17/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$138.00 ➝ $141.00High
3/4/2019JPMorgan Chase & Co.Reiterated RatingOverweight$140.00Medium
2/28/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$114.00 ➝ $138.00Low
2/26/2019Jefferies Financial GroupBoost TargetBuy$140.00Medium
2/26/2019Deutsche Bank AktiengesellschaftBoost TargetBuy$130.00Medium
2/26/2019UBS GroupBoost TargetBuy$125.00 ➝ $144.00Medium
2/25/2019Janney Montgomery ScottUpgradeNeutral ➝ BuyHigh
(Data available from 2/24/2019 forward)

News Sentiment Rating

0.88 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 32 very positive mentions
  • 35 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
7/29/2023
  • 12 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/28/2023
  • 21 very positive mentions
  • 20 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
9/27/2023
  • 24 very positive mentions
  • 32 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
10/27/2023
  • 10 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/26/2023
  • 27 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/26/2023
  • 37 very positive mentions
  • 29 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
1/25/2024
  • 38 very positive mentions
  • 36 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/24/2024

Current Sentiment

  • 38 very positive mentions
  • 36 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Danaher logo
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
Read More

Today's Range

Now: $253.84
Low: $252.58
High: $255.00

50 Day Range

MA: $236.56
Low: $224.58
High: $253.84

52 Week Range

Now: $253.84
Low: $182.09
High: $255.00

Volume

1,351,229 shs

Average Volume

2,755,968 shs

Market Capitalization

$187.77 billion

P/E Ratio

39.72

Dividend Yield

0.38%

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Danaher?

The following equities research analysts have issued reports on Danaher in the last twelve months: Bank of America Co., Barclays PLC, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, JPMorgan Chase & Co., KeyCorp, Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, SVB Securities, The Goldman Sachs Group, Inc., TheStreet, Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for DHR.

What is the current price target for Danaher?

14 Wall Street analysts have set twelve-month price targets for Danaher in the last year. Their average twelve-month price target is $266.00, suggesting a possible upside of 4.8%. SVB Securities has the highest price target set, predicting DHR will reach $300.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $205.00 for Danaher in the next year.
View the latest price targets for DHR.

What is the current consensus analyst rating for Danaher?

Danaher currently has 6 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DHR.

What other companies compete with Danaher?

How do I contact Danaher's investor relations team?

Danaher's physical mailing address is 2200 PENNSYLVANIA AVE. N.W SUITE 800W, WASHINGTON DC, 20037. The conglomerate's listed phone number is (202) 828-0850 and its investor relations email address is [email protected]. The official website for Danaher is www.danaher.com. Learn More about contacing Danaher investor relations.